SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MedImmune
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Dr. Bob who wrote (17)3/30/1997 12:17:00 PM
From: James Mortensen   of 416
 
Robert,

Your assessment is correct. I have a couple family members who have worked for years with one of the principal developers of the drug. The reputation of Respigam quickly outpaced the company's ability to increase supply. AND, supply will probably continue to be somewhat limited until the plant is in production. A limited supply in the face of inelastic demand (what are the alternatives?) will be a positive for Medimmune for years to come.

Dr. White, please continue with your informed input.

Regards, Jim.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News